PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
HOME > BUSINESS
BUSINESS
- Dr Morich’s 900 Million Yen Exec Pay Highest in Takeda
July 1, 2014
- Sanofi, Takeda Team Up to Raise Awareness of Diabetes
July 1, 2014
- Teijin Licenses ADA Deficiency Treatment from Sigma-Tau Pharma
July 1, 2014
- Gilead Submits NDA for HCV Treatment Sofosbuvir in Japan
July 1, 2014
- RaQualia, Eli Lilly of US Cease Research Collaboration for Analgesics
July 1, 2014
- Takeda CEO Defends Millennium, Nycomed Acquisitions as “Not Failures”
June 30, 2014
- Takeda CEO Counters Opposing Shareholders, Says Mr Weber Most Appropriate to Lead Drug Maker
June 30, 2014
- Astellas, UCB Japan File for Cimzia for Treatment-Naïve RA Patients
June 30, 2014
- Weber Becomes 1st Non-Japanese President of Takeda
June 27, 2014
- Eisai Files World’s 1st NDA for Anticancer Agent Lenvatinib in Japan
June 27, 2014
- BMKK to Begin Third-Party Investigation into Company Involvement in Sprycel Trial
June 26, 2014
- Kyowa Pres. Eyes Excursion into Authorized Generic Territory
June 26, 2014
- X-Linked Hypophosphatemia Treatment Improves Phosphate Metabolism in PI/II Study: Kyowa Kirin
June 26, 2014
- BI Japan Halts Development of Faldaprevir, Calls off Entry into Hepatitis C Field
June 26, 2014
- Nihon Chouzai Reaches Price Settlements with All Wholesalers; Expects to Avoid Reductions in Basic Dispensing Fees
June 25, 2014
- SGLT-2 Inhibitors Vigorously Increase in Anterio’s “Mind Share” Ranking in May
June 25, 2014
- Sanofi-Brand Generics of Diovan, Zometa Hit Shelves in Japan
June 24, 2014
- Diovan, Zometa Authorized Generics Now Available in Japan
June 24, 2014
- Plavix Grabs Top Spot in FY2013 Domestic Ethical Drug Sales Ranking
June 24, 2014
- Prevenar 13 Approved for Use in Elderly: Pfizer Japan
June 24, 2014
ページ
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…